{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T16:22:38Z","timestamp":1794932558344,"version":"4.9.1"},"reference-count":95,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1016\/j.neuropharm.2022.109373","type":"journal-article","created":{"date-parts":[[2022,12,9]],"date-time":"2022-12-09T00:45:24Z","timestamp":1670546724000},"page":"109373","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"special_numbering":"C","title":["Non-competitive AMPA glutamate receptors antagonism by perampanel as a strategy to counteract hippocampal hyper-excitability and cognitive deficits in cerebral amyloidosis"],"prefix":"10.1016","volume":"225","author":[{"given":"Laura","family":"Bellingacci","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Tallarico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Mancini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfredo","family":"Megaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"De Caro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rita","family":"Citraro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovambattista","family":"De Sarro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Tozzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimiliano","family":"Di Filippo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriam","family":"Sciaccaluga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilio","family":"Russo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0061-1608","authenticated-orcid":false,"given":"Antonio","family":"Leo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cinzia","family":"Costa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuropharm.2022.109373_bib1","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/S0197-4580(00)00124-X","article-title":"Inflammation and Alzheimer's disease","volume":"21","author":"Akiyama","year":"2000","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.neuropharm.2022.109373_bib2","doi-asserted-by":"crossref","first-page":"E2209","DOI":"10.1212\/WNL.0000000000007447","article-title":"Temporal lobe epilepsy: hippocampal pathology modulates connectome topology and controllability","volume":"92","author":"Bernhardt","year":"2019","journal-title":"Neurology"},{"key":"10.1016\/j.neuropharm.2022.109373_bib3","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1038\/nn.2801","article-title":"Neuronal activity regulates the regional vulnerability to amyloid-\u03b2 deposition","volume":"14","author":"Bero","year":"2011","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.neuropharm.2022.109373_bib4","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1089\/brain.2014.0236","article-title":"Network dysfunction in Alzheimer's disease: refining the disconnection hypothesis","volume":"4","author":"Brier","year":"2014","journal-title":"Brain Connect."},{"key":"10.1016\/j.neuropharm.2022.109373_bib5","doi-asserted-by":"crossref","first-page":"8740","DOI":"10.1073\/pnas.1206171109","article-title":"Critical role of soluble amyloid-\u03b2 for early hippocampal hyperactivity in a mouse model of Alzheimer's disease","volume":"109","author":"Busche","year":"2012","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.neuropharm.2022.109373_bib6","doi-asserted-by":"crossref","first-page":"233","DOI":"10.3233\/JAD-122131","article-title":"\u03b2CTF-correlated burst of hippocampal TNF\u03b1 occurs at a very early, pre-plaque stage in the TgCRND8 mouse model of Alzheimer's disease","volume":"36","author":"Cavanagh","year":"2013","journal-title":"J. Alzheim. Dis."},{"key":"10.1016\/j.neuropharm.2022.109373_bib7","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.neurobiolaging.2016.07.009","article-title":"Inhibiting tumor necrosis factor-\u03b1 before amyloidosis prevents synaptic deficits in an Alzheimer's disease model","volume":"47","author":"Cavanagh","year":"2016","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.neuropharm.2022.109373_bib8","doi-asserted-by":"crossref","first-page":"3442","DOI":"10.1523\/JNEUROSCI.5804-08.2009","article-title":"Inflammation triggers synaptic alteration and degeneration in experimental autoimmune encephalomyelitis","volume":"29","author":"Centonze","year":"2009","journal-title":"J. Neurosci."},{"key":"10.1016\/j.neuropharm.2022.109373_bib9","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20102450","article-title":"Glial cell AMPA Receptors in nervous system health, injury and disease","volume":"20","author":"Ceprian","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.neuropharm.2022.109373_bib10","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1006\/nlme.2001.4034","article-title":"Alzheimer amyloid \u03b2-peptide inhibits the late phase of long-term potentiation through calcineurin-dependent mechanisms in the hippocampal dentate gyrus","volume":"77","author":"Chen","year":"2002","journal-title":"Neurobiol. Learn. Mem."},{"key":"10.1016\/j.neuropharm.2022.109373_bib11","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s10571-016-0341-8","article-title":"The AMPAR antagonist perampanel attenuates traumatic brain injury through anti-oxidative and anti-inflammatory activity","volume":"37","author":"Chen","year":"2017","journal-title":"Cell. Mol. Neurobiol."},{"key":"10.1016\/j.neuropharm.2022.109373_bib12","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1517\/14728222.2014.874416","article-title":"Targeting \u03b1-amino-3-hydroxyl-5-methyl-4-isoxazole-propionate receptors in epilepsy","volume":"18","author":"Citraro","year":"2014","journal-title":"Expert Opin. Ther. Targets"},{"key":"10.1016\/j.neuropharm.2022.109373_bib13","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.brainresbull.2019.08.001","article-title":"Evaluation of the effects of liraglutide on the development of epilepsy and behavioural alterations in two animal models of epileptogenesis","volume":"153","author":"Citraro","year":"2019","journal-title":"Brain Res. Bull."},{"key":"10.1016\/j.neuropharm.2022.109373_bib14","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1111\/epi.13629","article-title":"Perampanel effects in the WAG\/Rij rat model of epileptogenesis, absence epilepsy, and comorbid depressive-like behavior","volume":"58","author":"Citraro","year":"2017","journal-title":"Epilepsia"},{"key":"10.1016\/j.neuropharm.2022.109373_bib15","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/sj.npp.1301559","article-title":"Synaptic plasticity: multiple forms, functions, and mechanisms","volume":"33","author":"Citri","year":"2008","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2022.109373_bib16","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1038\/nrn1556","article-title":"Receptor trafficking and synaptic plasticity","volume":"5","author":"Collingridge","year":"2004","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.neuropharm.2022.109373_bib17","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.neurobiolaging.2016.08.025","article-title":"Epilepsy, amyloid-\u03b2, and D1 dopamine receptors: a possible pathogenetic link?","volume":"48","author":"Costa","year":"2016","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.neuropharm.2022.109373_bib18","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2020.620221","article-title":"Analgesic and anti-inflammatory effects of perampanel in acute and chronic pain models in mice: interaction with the cannabinergic system","volume":"11","author":"De Caro","year":"2021","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.neuropharm.2022.109373_bib19","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.neures.2004.05.007","article-title":"Seizure susceptibility to various convulsant stimuli in dystrophin-deficient mdx mice","volume":"50","author":"De Sarro","year":"2004","journal-title":"Neurosci. Res."},{"key":"10.1016\/j.neuropharm.2022.109373_bib20","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/j.pbb.2004.01.012","article-title":"Seizure susceptibility to various convulsant stimuli of knockout interleukin-6 mice","volume":"77","author":"De Sarro","year":"2004","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.neuropharm.2022.109373_bib21","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1111\/epi.16918","article-title":"Astrocyte and glutamate involvement in the pathogenesis of epilepsy in Alzheimer's disease","volume":"62","author":"Dejakaisaya","year":"2021","journal-title":"Epilepsia"},{"key":"10.1016\/j.neuropharm.2022.109373_bib22","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1023\/A:1023832305702","article-title":"Alzheimer's disease as a disconnection syndrome?","volume":"13","author":"Delbeuck","year":"2003","journal-title":"Neuropsychol. Rev."},{"key":"10.1016\/j.neuropharm.2022.109373_bib23","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1080\/14656566.2017.1392509","article-title":"AMPA receptors and perampanel behind selected epilepsies: current evidence and future perspectives","volume":"18","author":"Di Bonaventura","year":"2017","journal-title":"Expet Opin. Pharmacother."},{"key":"10.1016\/j.neuropharm.2022.109373_bib24","article-title":"Persistent activation of microglia and NADPH oxidase [corrected] drive hippocampal dysfunction in experimental multiple sclerosis","volume":"6","author":"Di Filippo","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.neuropharm.2022.109373_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2021.110094","article-title":"Interleukin-17 affects synaptic plasticity and cognition in an experimental model of multiple sclerosis","volume":"37","author":"Di Filippo","year":"2021","journal-title":"Cell Rep."},{"key":"10.1016\/j.neuropharm.2022.109373_bib26","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.tips.2008.06.005","article-title":"Neuroinflammation and synaptic plasticity: theoretical basis for a novel, immune-centred, therapeutic approach to neurological disorders","volume":"29","author":"Di Filippo","year":"2008","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.neuropharm.2022.109373_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2021.108710","article-title":"AMPA receptor trafficking and LTP: carboxy-termini, amino-termini and TARPs","volume":"197","author":"D\u00edaz-Alonso","year":"2021","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2022.109373_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.expneurol.2021.113916","article-title":"Differential glutamate receptor expression and function in the hippocampus, anterior temporal lobe and neocortex in a pilocarpine model of temporal lobe epilepsy","volume":"347","author":"Dubey","year":"2022","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.neuropharm.2022.109373_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.nlm.2011.08.003","article-title":"The A\u03b2 oligomer hypothesis for synapse failure and memory loss in Alzheimer's disease","author":"Ferreira","year":"2011","journal-title":"Neurobiol. Learn. Mem."},{"key":"10.1016\/j.neuropharm.2022.109373_bib30","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1097\/FTD.0000000000000350","article-title":"Development and validation of an HPLC-UV assay for the therapeutic monitoring of the new antiepileptic drug perampanel in human plasma","volume":"38","author":"Franco","year":"2016","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.neuropharm.2022.109373_bib31","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2019.01151","article-title":"Characterization of epileptic spiking associated with brain amyloidosis in APP\/PS1 mice","volume":"10","author":"Gureviciene","year":"2019","journal-title":"Front. Neurol."},{"key":"10.1016\/j.neuropharm.2022.109373_bib32","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1111\/j.1528-1167.2011.03109.x","article-title":"Perampanel: a novel, orally active, noncompetitive AMPA-receptor antagonist that reduces seizure activity in rodent models of epilepsy","volume":"52","author":"Hanada","year":"2011","journal-title":"Epilepsia"},{"key":"10.1016\/j.neuropharm.2022.109373_bib33","article-title":"Tipping the scales: peptide-dependent dysregulation of neural circuit dynamics in Alzheimer's disease","volume":"107","author":"Harris","year":"2020","journal-title":"J. Clean. Prod."},{"key":"10.1016\/j.neuropharm.2022.109373_bib34","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2021.108569","article-title":"Kainate and AMPA receptors in epilepsy: cell biology, signalling pathways and possible crosstalk","volume":"195","author":"Henley","year":"2021","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2022.109373_bib35","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1038\/nrn.2016.37","article-title":"Synaptic AMPA receptor composition in development, plasticity and disease","volume":"17","author":"Henley","year":"2016","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.neuropharm.2022.109373_bib36","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/j.neuron.2006.10.035","article-title":"AMPAR removal underlies Abeta-induced synaptic depression and dendritic spine loss","volume":"52","author":"Hsieh","year":"2006","journal-title":"Neuron"},{"key":"10.1016\/j.neuropharm.2022.109373_bib37","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1002\/cpdd.1107","article-title":"Intravenous perampanel as an interchangeable alternative to oral perampanel: a randomized, crossover, phase I pharmacokinetic and safety study","volume":"11","author":"Hussein","year":"2022","journal-title":"Clin. Pharmacol. Drug Dev."},{"key":"10.1016\/j.neuropharm.2022.109373_bib38","doi-asserted-by":"crossref","DOI":"10.3791\/52805","article-title":"Stereotaxic infusion of oligomeric amyloid-beta into the mouse hippocampus","author":"Jean","year":"2015","journal-title":"JoVE"},{"key":"10.1016\/j.neuropharm.2022.109373_bib39","article-title":"Inflammation-mediated memory dysfunction and effects of a ketogenic diet in a murine model of multiple sclerosis","volume":"7","author":"Kim","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.neuropharm.2022.109373_bib40","doi-asserted-by":"crossref","DOI":"10.3390\/biom9100638","article-title":"The novel direct modulatory effects of perampanel, an antagonist of AMPA receptors, on voltage-gated sodium and M-type potassium currents","volume":"9","author":"Lai","year":"2019","journal-title":"Biomolecules"},{"key":"10.1016\/j.neuropharm.2022.109373_bib41","doi-asserted-by":"crossref","DOI":"10.1016\/j.pnpbp.2019.109652","article-title":"Cognitive impairment in the WAG\/Rij rat absence model is secondary to absence seizures and depressive-like behavior","volume":"94","author":"Leo","year":"2019","journal-title":"Prog. Neuro Psychopharmacol. Biol. Psychiatr."},{"key":"10.1016\/j.neuropharm.2022.109373_bib42","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2021.108782","article-title":"Increased efficacy of combining prebiotic and postbiotic in mouse models relevant to autism and depression","volume":"198","author":"Leo","year":"2021","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2022.109373_bib43","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1111\/epi.14082","article-title":"The role of AMPA receptors and their antagonists in status epilepticus","volume":"59","author":"Leo","year":"2018","journal-title":"Epilepsia"},{"key":"10.1016\/j.neuropharm.2022.109373_bib44","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1007\/s13311-020-00893-8","article-title":"IL-6 receptor blockade by tocilizumab has anti-absence and anti-epileptogenic effects in the WAG\/Rij rat model of absence epilepsy","volume":"17","author":"Leo","year":"2020","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.neuropharm.2022.109373_bib45","article-title":"Epilepsy and Alzheimer's disease: current concepts and treatment perspective on two closely related pathologies","volume":"20","author":"Leo","year":"2022","journal-title":"Curr. Neuropharmacol."},{"key":"10.1016\/j.neuropharm.2022.109373_bib46","doi-asserted-by":"crossref","first-page":"433","DOI":"10.2174\/1567205011310040008","article-title":"Autophagy enhancer carbamazepine alleviates memory deficits and cerebral amyloid-\u03b2 pathology in a mouse model of Alzheimer's disease","volume":"10","author":"Li","year":"2013","journal-title":"Curr. Alzheimer Res."},{"key":"10.1016\/j.neuropharm.2022.109373_bib47","article-title":"A mechanistic hypothesis for the impairment of synaptic plasticity by soluble A\u03b2 oligomers from Alzheimer's brain","author":"Li","year":"2020","journal-title":"J. Neurochem."},{"key":"10.1016\/j.neuropharm.2022.109373_bib95","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0022-3565(25)03549-9","article-title":"A simplified method of evaluating dose-effect experiments","volume":"96","author":"Litchfield","year":"1949","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2022.109373_bib48","doi-asserted-by":"crossref","first-page":"655","DOI":"10.3233\/JAD-2010-091654","article-title":"Amyloid-\u03b2 decreases cell-surface AMPA receptors by increasing intracellular calcium and phosphorylation of GluR2","volume":"21","author":"Liu","year":"2010","journal-title":"J. Alzheim. Dis."},{"key":"10.1016\/j.neuropharm.2022.109373_bib49","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1038\/29312","article-title":"Calcium-permeable AMPA receptors mediate long-term potentiation in interneurons in the amygdala","volume":"394","author":"Mahanty","year":"1998","journal-title":"Nature"},{"key":"10.1016\/j.neuropharm.2022.109373_bib50","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1098\/rstb.2002.1233","article-title":"AMPA receptor trafficking and long-term potentiation","volume":"358","author":"Malinow","year":"2003","journal-title":"Philos. Trans. R. Soc. Lond. B Biol. Sci."},{"key":"10.1016\/j.neuropharm.2022.109373_bib51","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.644294","article-title":"Neuro-immune cross-talk in the striatum: from basal ganglia physiology to circuit dysfunction","volume":"12","author":"Mancini","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.neuropharm.2022.109373_bib52","doi-asserted-by":"crossref","DOI":"10.1016\/j.nbd.2020.104848","article-title":"Low doses of Perampanel protect striatal and hippocampal neurons against in vitro ischemia by reversing the ischemia-induced alteration of AMPA receptor subunit composition","volume":"140","author":"Mazzocchetti","year":"2020","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.neuropharm.2022.109373_bib53","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.neulet.2017.06.056","article-title":"The glutamate receptor antagonists CNQX and MPEP decrease fast ripple events in rats treated with kainic acid","volume":"655","author":"Medina-Ceja","year":"2017","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.neuropharm.2022.109373_bib94","doi-asserted-by":"crossref","first-page":"27311","DOI":"10.1074\/jbc.M111.227504","article-title":"Soluble oligomers of amyloid-\u03b2 peptide disrupt membrane trafficking of \u03b1-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptor contributing to early synapse dysfunction","volume":"286","author":"Mi\u00f1ano-Molina","year":"2011","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.neuropharm.2022.109373_bib54","doi-asserted-by":"crossref","first-page":"3453","DOI":"10.1523\/JNEUROSCI.5215-08.2009","article-title":"Amyloid \u03b2-induced neuronal hyperexcitability triggers progressive epilepsy","volume":"29","author":"Minkeviciene","year":"2009","journal-title":"J. Neurosci."},{"key":"10.1016\/j.neuropharm.2022.109373_bib55","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a006338","article-title":"Neurotoxicity of amyloid \u03b2-protein: synaptic and network dysfunction","volume":"2","author":"Mucke","year":"2012","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"10.1016\/j.neuropharm.2022.109373_bib56","doi-asserted-by":"crossref","first-page":"4778","DOI":"10.1007\/s12035-020-02062-6","article-title":"Metabolic alterations predispose to seizure development in high-fat diet-treated mice: the role of metformin","volume":"57","author":"Nesci","year":"2020","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.neuropharm.2022.109373_bib57","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1523\/JNEUROSCI.20-01-00251.2000","article-title":"AMPA-kainate subtypes of glutamate receptor in rat cerebral microglia","volume":"20","author":"Noda","year":"2000","journal-title":"J. Neurosci."},{"key":"10.1016\/j.neuropharm.2022.109373_bib58","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/j.neuron.2007.07.025","article-title":"Aberrant excitatory neuronal activity and compensatory remodeling of inhibitory hippocampal circuits in mouse models of Alzheimer's disease","volume":"55","author":"Palop","year":"2007","journal-title":"Neuron"},{"key":"10.1016\/j.neuropharm.2022.109373_bib59","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1038\/nn.2583","article-title":"Amyloid-\u0392-induced neuronal dysfunction in Alzheimer's disease: from synapses toward neural networks","volume":"13","author":"Palop","year":"2010","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.neuropharm.2022.109373_bib60","series-title":"Paxinos and Franklin's the Mouse Brain in Stereotaxic Coordinates","author":"Paxinos","year":"2001"},{"key":"10.1016\/j.neuropharm.2022.109373_bib61","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.2174\/1567205017666191213162233","article-title":"Brain arrhythmias induced by amyloid beta and inflammation: involvement in Alzheimer's disease and other inflammation-related pathologies","volume":"16","author":"Pe\u00f1a-Ortega","year":"2019","journal-title":"Curr. Alzheimer Res."},{"key":"10.1016\/j.neuropharm.2022.109373_bib62","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1111\/epi.14456","article-title":"Perampanel: does it have broad-spectrum potential?","volume":"60","author":"Potschka","year":"2019","journal-title":"Epilepsia"},{"key":"10.1016\/j.neuropharm.2022.109373_bib63","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1002\/ana.23570","article-title":"Calcium-permeable AMPA receptors are expressed in a rodent model of status epilepticus","volume":"72","author":"Rajasekaran","year":"2012","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.neuropharm.2022.109373_bib64","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1515\/revneuro-2017-0063","article-title":"Amyloid toxicity in Alzheimer's disease","volume":"29","author":"Reiss","year":"2018","journal-title":"Rev. Neurosci."},{"key":"10.1016\/j.neuropharm.2022.109373_bib65","doi-asserted-by":"crossref","DOI":"10.1155\/2018\/8430123","article-title":"Tumor necrosis factor and interleukin-1 \u03b2 modulate synaptic plasticity during neuroinflammation","author":"Rizzo","year":"2018","journal-title":"Neural Plast."},{"key":"10.1016\/j.neuropharm.2022.109373_bib66","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1111\/ane.12099","article-title":"AMPA receptors as a molecular target in epilepsy therapy","volume":"127","author":"Rogawski","year":"2013","journal-title":"Acta Neurol. Scand."},{"key":"10.1016\/j.neuropharm.2022.109373_bib67","doi-asserted-by":"crossref","DOI":"10.1002\/brb3.1825","article-title":"Remodeling of brain morphology in temporal lobe epilepsy","volume":"10","author":"Roggenhofer","year":"2020","journal-title":"Brain Behav."},{"key":"10.1016\/j.neuropharm.2022.109373_bib68","doi-asserted-by":"crossref","DOI":"10.1038\/s41582-021-00505-9","article-title":"Amyloid-\u03b2: a potential link between epilepsy and cognitive decline","author":"Romoli","year":"2021","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.neuropharm.2022.109373_bib69","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.yebeh.2013.05.002","article-title":"Lamotrigine positively affects the development of psychiatric comorbidity in epileptic animals, while psychiatric comorbidity aggravates seizures","volume":"28","author":"Russo","year":"2013","journal-title":"Epilepsy Behav."},{"key":"10.1016\/j.neuropharm.2022.109373_bib70","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1038\/s41577-021-00508-z","article-title":"Neuromodulation by the immune system: a focus on cytokines","volume":"21","author":"Salvador","year":"2021","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.neuropharm.2022.109373_bib71","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2021.109786","article-title":"\u03b2-Amyloid disruption of LTP\/LTD balance is mediated by AKAP150-anchored PKA and Calcineurin regulation of Ca 2+-permeable AMPA receptors","volume":"37","author":"Sanderson","year":"2021","journal-title":"Cell Rep."},{"key":"10.1016\/j.neuropharm.2022.109373_bib72","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1097\/WNR.0000000000000601","article-title":"Levetiracetam inhibits oligomeric A\u03b2-induced glutamate release from human astrocytes","volume":"27","author":"Sanz-Blasco","year":"2016","journal-title":"Neuroreport"},{"key":"10.1016\/j.neuropharm.2022.109373_bib73","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22115991","article-title":"An unbalanced synaptic transmission: cause or consequence of the amyloid oligomers neurotoxicity?","volume":"22","author":"Sciaccaluga","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.neuropharm.2022.109373_bib74","first-page":"298","article-title":"Alzheimer \u2019 s disease is a synaptic failure author (s)","volume":"80","author":"Selkoe","year":"2002","journal-title":"Dennis J . Selkoe. Science"},{"key":"10.1016\/j.neuropharm.2022.109373_bib75","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1093\/brain\/awy022","article-title":"Cognition and dementia in older patients with epilepsy","volume":"141","author":"Sen","year":"2018","journal-title":"Brain"},{"key":"10.1016\/j.neuropharm.2022.109373_bib76","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(19)33064-8","article-title":"Epilepsy in older people","author":"Sen","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.neuropharm.2022.109373_bib77","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1038\/nm1782","article-title":"Amyloid-\u03b2 protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory","volume":"14","author":"Shankar","year":"2008","journal-title":"Nat. Med."},{"key":"10.1016\/j.neuropharm.2022.109373_bib78","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1002\/glia.20940","article-title":"Role of glutamate and its receptors and insulin-like growth factors in hypoxia induced periventricular white matter injury","volume":"58","author":"Sivakumar","year":"2010","journal-title":"Glia"},{"key":"10.1016\/j.neuropharm.2022.109373_bib79","doi-asserted-by":"crossref","first-page":"11612","DOI":"10.1074\/jbc.M210207200","article-title":"In vitro characterization of conditions for amyloid-beta peptide oligomerization and fibrillogenesis","volume":"278","author":"Stine","year":"2003","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.neuropharm.2022.109373_bib80","doi-asserted-by":"crossref","first-page":"2702","DOI":"10.1007\/s12035-021-02720-3","article-title":"N-acetylcysteine aggravates seizures while improving depressive-like and cognitive impairment comorbidities in the WAG\/Rij rat model of absence epilepsy","volume":"59","author":"Tallarico","year":"2022","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.neuropharm.2022.109373_bib81","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1111\/epi.16788","article-title":"Inflammation, ictogenesis, and epileptogenesis: an exploration through human disease","volume":"62","author":"Tan","year":"2021","journal-title":"Epilepsia"},{"key":"10.1016\/j.neuropharm.2022.109373_bib82","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/j.trci.2019.10.003","article-title":"Amyloid-\u03b2 oligomers suppress subunit-specific glutamate receptor increase during LTP","volume":"5","author":"Tanaka","year":"2019","journal-title":"Alzheimer's Dementia"},{"key":"10.1016\/j.neuropharm.2022.109373_bib83","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/1750-1326-9-48","article-title":"Oligomeric A\u03b2-induced synaptic dysfunction in Alzheimer's disease","volume":"9","author":"Tu","year":"2014","journal-title":"Mol. Neurodegener."},{"key":"10.1016\/j.neuropharm.2022.109373_bib84","doi-asserted-by":"crossref","DOI":"10.1111\/epi.17355","article-title":"Higher susceptibility to 6 Hz corneal kindling and lower responsiveness to antiseizure drugs in mouse models of Alzheimer's disease","author":"Vande Vyver","year":"2022","journal-title":"Epilepsia"},{"key":"10.1016\/j.neuropharm.2022.109373_bib85","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1038\/416535a","article-title":"Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo","volume":"416","author":"Walsh","year":"2002","journal-title":"Nature"},{"key":"10.1016\/j.neuropharm.2022.109373_bib86","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.bbrc.2021.12.038","article-title":"Effects of perampanel on cognitive behavior and GluR1 expression in immature mice of temporal lobe epilepsy","volume":"588","author":"Wang","year":"2022","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.neuropharm.2022.109373_bib87","doi-asserted-by":"crossref","DOI":"10.1038\/srep10934","article-title":"Intracellular oligomeric amyloid-beta rapidly regulates GluA1 subunit of AMPA receptor in the hippocampus","volume":"5","author":"Whitcomb","year":"2015","journal-title":"Sci. Rep."},{"key":"10.1016\/j.neuropharm.2022.109373_bib88","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.neuropharm.2017.09.031","article-title":"Valproic acid and its congener propylisopropylacetic acid reduced the amount of soluble amyloid-\u03b2 oligomers released from 7PA2 cells","volume":"128","author":"Williams","year":"2018","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2022.109373_bib89","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.seizure.2021.12.001","article-title":"The impact of perampanel on cognition: a systematic review of studies employing standardized tests in patients with epilepsy","volume":"94","author":"Witt","year":"2022","journal-title":"Seizure"},{"key":"10.1016\/j.neuropharm.2022.109373_bib90","doi-asserted-by":"crossref","first-page":"863","DOI":"10.3233\/JAD-143162","article-title":"Lamotrigine reduces \u03b2-Site A\u03b2PP-Cleaving enzyme 1 protein levels through induction of autophagy","volume":"46","author":"Wu","year":"2015","journal-title":"J. Alzheimers. Dis."},{"key":"10.1016\/j.neuropharm.2022.109373_bib91","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/j.celrep.2015.04.017","article-title":"Chronic optogenetic activation augments a\u03b2 pathology in a mouse model of Alzheimer disease","volume":"11","author":"Yamamoto","year":"2015","journal-title":"Cell Rep."},{"key":"10.1016\/j.neuropharm.2022.109373_bib92","doi-asserted-by":"crossref","first-page":"5177","DOI":"10.1111\/bph.15253","article-title":"Perampanel reduces paroxysmal depolarizing shift and inhibitory synaptic input in excitatory neurons to inhibit epileptic network oscillations","volume":"177","author":"Yang","year":"2020","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2022.109373_bib93","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1126\/science.aay0198","article-title":"A vicious cycle of \u03b2 amyloid-dependent neuronal hyperactivation","volume":"365","author":"Zott","year":"2019","journal-title":"Science"}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390822004324?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390822004324?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T07:20:13Z","timestamp":1758439213000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0028390822004324"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":95,"alternative-id":["S0028390822004324"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2022.109373","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Non-competitive AMPA glutamate receptors antagonism by perampanel as a strategy to counteract hippocampal hyper-excitability and cognitive deficits in cerebral amyloidosis","name":"articletitle","label":"Article Title"},{"value":"Neuropharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuropharm.2022.109373","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"109373"}}